On November 4, SKB BIO rose 3.59% in Regular Trading, with shares trading at HK$414.4 and turnover of HK$73.84 million.
The move was accompanied by continued positive progress around its core product sacituzumab tirumotecan, which has recently provided support to sentiment.
Background details show the company recently presented three Phase III studies for sac-TMT at ESMO, including lung cancer data indicating progression-free survival and overall survival benefit. In addition, its new indication application for sac-TMT combined with pembrolizumab as first-line treatment for PD-L1-negative non-squamous NSCLC has been accepted for review in China. After these updates, several brokers maintained positive ratings, with target prices ranging from HK$520 to HK$678.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments